Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Last trade$51.79
Day change-$1.38 (-2.60%)
Day range$51.37 – $53.83
Volume1,762,813
Market cap$7.41B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.41B
Price / earnings
—
Price / book
-23.06×
Price / sales
65.38×
EV / sales
73.75×
EV / EBITDA
-12.03×
Profitability
Earnings per share
-$5.58
Return on assets
-42.63%
Return on equity
242.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-3.59×
Current ratio
3.36×
Quick ratio
3.36×
Cash ratio
0.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$588.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CYTK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$47.56M
$28.62M
$19.36M
$17.76M
$1.94M
$66.77M
$1.58M
$16.93M
Cost of revenue
-$454K
$2.73M
$2.55M
$0
$0
$0
$1.58M
$0
Gross profit
$48.01M
$25.89M
$16.8M
$17.76M
$1.94M
$66.77M
$0
$16.93M
Selling, general and administrative
$113.14M
$104.4M
$104.9M
$91.72M
$69.46M
$65.72M
$57.37M
$62.34M
Research and development
$99.29M
$97.81M
$95.53M
$104.4M
$97.3M
$110.14M
$98.26M
$93.63M
Total operating expenses
$215.1M
$205.07M
$200.42M
$196.12M
$168.69M
$178.28M
$155.63M
$155.97M
Operating income
-$167.09M
-$179.17M
-$183.62M
-$178.37M
-$166.76M
-$111.51M
-$155.63M
-$139.04M
Interest expense
-$14.84M
-$14.65M
-$14.52M
$27.95M
-$11.35M
-$11.08M
-$8.87M
$26.22M
Income before taxes
-$190.07M
-$198.76M
-$206.03M
-$61.78M
-$184.93M
-$134.37M
-$161.38M
-$150.02M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$190.07M
-$198.76M
-$206.03M
-$61.78M
-$184.93M
-$134.37M
-$161.38M
-$150.02M
Net income attributable to common shareholders
-$190.07M
-$198.76M
-$206.03M
-$183.03M
-$306.18M
-$134.37M
-$161.38M
-$150.02M
EBITDA
-$163.44M
-$175.54M
-$180.24M
-$175.51M
-$164.08M
-$109.22M
-$153.33M
-$136.66M
Basic earnings per share
-$1.37
-$1.50
-$1.67
-$1.49
-$2.55
-$1.12
-$1.36
-$1.26
Diluted earnings per share
-$1.37
-$1.50
-$1.67
-$1.49
-$2.55
-$1.12
-$1.36
-$1.26
Recent news
Company coverage with links to the original publishers.
The FDA approved an updated prescribing label for Cytokinetics' MYQORZO (aficamten), a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), to include Phase 3 MAPLE-HCM trial data comparing it to the beta-blocker metoprolol. MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden, and cardiac biomarkers compared to metoprolol, making it the only cardiac myosin inhibitor with such comparative evidence in its U.S. label.
Bristol Myers Squibb expanded Camzyos' FDA approval to pediatric patients, broadening its addressable market in the obstructive hypertrophic cardiomyopathy space. Camzyos sales surged 61% to $1.1 billion, while Eliquis revenues rose 21% to $13.3 billion in nine months. However, BMY faces competitive pressure from Cytokinetics' newly approved Myqorzo and potential competition from Edgewise Therapeutics, while upcoming patent expirations pose longer-term revenue challenges.
Cytokinetics is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +0.44% and Zacks Rank #3 (Hold). The company is projected to report a quarterly loss of $1.50 per share with revenues of $42.01 million, up 2065.5% year-over-year. The stock has beaten consensus EPS estimates in 2 of the last 4 quarters.
Cytokinetics announced it will report third quarter 2026 results on November 4, 2026, followed by a conference call. The company highlighted positive progress with MYQORZO® (aficamten) approved across multiple regions for obstructive hypertrophic cardiomyopathy, and plans to submit a Supplemental New Drug Application in Q4 2026 following positive Phase 3 results for non-obstructive HCM treatment.